| Outcome: new AKI [OR (95% CI)] (n = 420)a | |
---|---|---|
 | Unadjusted | Adjusted |
Cumulative FB at 48Â h | Â | Â |
 < − 2% (n = 20) | 0.76 (0.26, 2.19) | 0.80 (0.26, 2.47) |
 − 2% to 0% (n = 128) | 1.40 (0.87, 2.27) | 1.57 (0.92, 2.65) |
 0% to + 2% (n = 180) | Reference | Reference |
 >  + 2% (n = 92) | 3.08 (1.83, 5.20)*** | 2.55 (1.46, 4.50) ** |
Invasive ventilation | – | 1.32 (0.62, 2.84) |
Remdesivir | – | 0.79 (0.45, 1.38) |
Steroids | – | 1.49 (0.73, 2.98) |
IL-6 antagonists | – | 0.78 (0.42, 1.47) |
Non-renal SOFA score | – | 1.19 (1.04, 1.36)** |
Baseline diuretics | – | 1.06 (0.63, 1.78) |
Max PEEP in first 48 h | – | 1.03 (0.97, 1.09) |
Vasopressor use | – | 0.57 (0.33, 0.98)* |
Delta FB between day 1 and 2 [mL/kg] | – | 0.99 (0.97, 1.00) |
 | Outcome: new KRT [OR (95% CI)] (n = 648)b | |
---|---|---|
 | Unadjusted | Adjusted |
Cumulative FB at 48Â h | Â | Â |
 < − 2% (n = 25) | 0.26 (0.03, 1.99) | 0.44 (0.06, 3.55) |
 − 2% to 0% (n = 161) | 0.79 (0.43, 1.44) | 1.04 (0.53, 1.89) |
 0% to + 2% (n = 269) | Reference | Reference |
 + 2% to + 4% (n = 136) | 1.70 (0.99, 2.91) | 1.57 (0.87, 2.82) |
 >  + 4% (n = 57) | 3.94 (2.09, 7.45)*** | 4.16 (2.03, 8.51)*** |
Invasive ventilation | – | 2.70 (1.10, 6.66)* |
Remdesivir | – | 0.61 (0.29, 1.26) |
Steroids | – | 3.22 (1.58, 6.54)** |
IL-6 antagonists | – | 0.84 (0.37, 1.89) |
Non-renal SOFA score | – | 0.98 (0.86, 1.12) |
Baseline diuretics | – | 1.14 (0.68, 1.94) |
Max PEEP in first 48 h | – | 1.00 (0.94, 1.07) |
Vasopressor use | – | 0.76 (0.45, 1.27) |
Delta FB between day 1 and 2 [mL/kg] | – | 1.01 (0.99, 1.03) |